BOLT Bolt Biotherapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BOLT

Price (delayed)

$3.665

Market cap

$7.06M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$16.51

Enterprise value

$15.62M

?
Relative Growth: Rel. Growth: 44
Relative Strength: Rel. Strength: 12
Relative Valuation: Rel. Valuation: 25
Relative Profitability: Rel. Profitability: 36

Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Bolt Biotherapeutics’ pipeline candidates are built on the Company’s deep expertise in myeloid biology and ...

Highlights
The company's net income rose by 43% YoY and by 2.8% QoQ
The EPS has grown by 38% YoY
The revenue fell by 28% QoQ but it rose by 13% YoY
Bolt Biotherapeutics's gross profit has decreased by 28% from the previous quarter but it has increased by 13% YoY
The equity has plunged by 67% YoY and by 36% from the previous quarter
The quick ratio has contracted by 28% from the previous quarter and by 22% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.boltbio.com
Peers: NPKI NOV FTI GEOS

Key stats

What are the main financial stats of BOLT

BOLT stock price

How has the Bolt Biotherapeutics stock price performed over time
Intraday
14.53%
1 week
9.4%
1 month
-8.83%
1 year
-25.05%
YTD
-32.97%
QTD
-4.81%

Financial performance

How have Bolt Biotherapeutics's revenue and profit performed over time
Revenue
$4.7M
Gross profit
$4.7M
Operating income
-$30.76M
Net income
-$28.74M
Gross margin
100%
Net margin
-611.5%
The net margin has grown by 50% YoY but it has contracted by 34% from the previous quarter
Bolt Biotherapeutics's operating margin has soared by 50% YoY but it has decreased by 35% from the previous quarter
The operating income is up by 44% year-on-year and by 2.6% since the previous quarter
The company's net income rose by 43% YoY and by 2.8% QoQ

Price vs fundamentals

How does BOLT's price correlate with its fundamentals

Growth

What is Bolt Biotherapeutics's growth rate over time

Valuation

What is Bolt Biotherapeutics stock price valuation
P/E
N/A
P/B
0.56
P/S
1.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.32
The EPS has grown by 38% YoY
The equity has plunged by 67% YoY and by 36% from the previous quarter
BOLT's P/B is 40% above its last 4 quarters average of 0.4 and 12% above its 5-year quarterly average of 0.5
The stock's P/S is 97% less than its 5-year quarterly average of 44.8 and 6% less than its last 4 quarters average of 1.4
The revenue fell by 28% QoQ but it rose by 13% YoY

Efficiency

How efficient is Bolt Biotherapeutics business performance
The ROS has grown by 50% YoY but it has contracted by 34% from the previous quarter
The ROE fell by 34% YoY and by 25% QoQ
Bolt Biotherapeutics's ROIC has decreased by 14% from the previous quarter but it has increased by 2.3% YoY
Bolt Biotherapeutics's ROA has decreased by 13% from the previous quarter

Dividends

What is BOLT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BOLT.

Financial health

How did Bolt Biotherapeutics financials performed over time
The total assets is 46% greater than the total liabilities
The total assets has declined by 47% year-on-year and by 16% since the previous quarter
The quick ratio has contracted by 28% from the previous quarter and by 22% YoY
The debt is 71% more than the equity
BOLT's debt to equity has soared by 176% YoY and by 51% from the previous quarter
The equity has plunged by 67% YoY and by 36% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.